These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis. Wang Y; Yella JK; Ghandikota S; Cherukuri TC; Ediga HH; Madala SK; Jegga AG Ther Adv Respir Dis; 2020; 14():1753466620971143. PubMed ID: 33167785 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies targeting pro-fibrotic macrophages in interstitial lung disease. Isshiki T; Vierhout M; Naiel S; Ali P; Yazdanshenas P; Kumaran V; Yang Z; Dvorkin-Gheva A; Rullo AF; Kolb MRJ; Ask K Biochem Pharmacol; 2023 May; 211():115501. PubMed ID: 36921632 [TBL] [Abstract][Full Text] [Related]
4. Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival. Keow J; Cecchini MJ; Jayawardena N; Zompatori M; Joseph MG; Mura M Respir Res; 2022 Jun; 23(1):147. PubMed ID: 35672770 [TBL] [Abstract][Full Text] [Related]
5. Repurposing Anticancer Drugs for the Treatment of Idiopathic Pulmonary Fibrosis and Antifibrotic Drugs for the Treatment of Cancer: State of the Art. Paliogiannis P; Fois SS; Fois AG; Cossu A; Palmieri G; Pintus G Curr Med Chem; 2021; 28(11):2234-2247. PubMed ID: 32748739 [TBL] [Abstract][Full Text] [Related]
6. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease. Jung SM; Park KS; Kim KJ Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701 [TBL] [Abstract][Full Text] [Related]
7. Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformatics-derived composite score. Karatzas E; Bourdakou MM; Kolios G; Spyrou GM Sci Rep; 2017 Oct; 7(1):12569. PubMed ID: 28974751 [TBL] [Abstract][Full Text] [Related]
8. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients. Feng H; Zhao Y; Li Z; Kang J Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705 [TBL] [Abstract][Full Text] [Related]
9. Transcriptomic analysis of choroidal neovascularization reveals dysregulation of immune and fibrosis pathways that are attenuated by a novel anti-fibrotic treatment. Brandli A; Khong FL; Kong RCK; Kelly DJ; Fletcher EL Sci Rep; 2022 Jan; 12(1):859. PubMed ID: 35039609 [TBL] [Abstract][Full Text] [Related]
10. Prominence of IL6, IGF, TLR, and Bioenergetics Pathway Perturbation in Lung Tissues of Scleroderma Patients With Pulmonary Fibrosis. Renaud L; da Silveira WA; Takamura N; Hardiman G; Feghali-Bostwick C Front Immunol; 2020; 11():383. PubMed ID: 32210969 [TBL] [Abstract][Full Text] [Related]
11. Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Ghazipura M; Mammen MJ; Herman DD; Hon SM; Bissell BD; Macrea M; Kheir F; Khor YH; Knight SL; Raghu G; Wilson KC; Hossain T Ann Am Thorac Soc; 2022 Jun; 19(6):1040-1049. PubMed ID: 35499854 [No Abstract] [Full Text] [Related]
12. Transcriptomic profiling reveals disease-specific characteristics of epithelial cells in idiopathic pulmonary fibrosis. Boesch M; Baty F; Brutsche MH; Tamm M; Roux J; Knudsen L; Gazdhar A; Geiser T; Khan P; Hostettler KE Respir Res; 2020 Jun; 21(1):165. PubMed ID: 32605572 [TBL] [Abstract][Full Text] [Related]
13. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A; Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455 [TBL] [Abstract][Full Text] [Related]
14. Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis. Wang S; Liu M; Li X; Zhang J; Wang F; Zhang C; Roden A; Ryu JH; Warrington KJ; Sun J; Matteson EL; Tschumperlin DJ; Vassallo R FASEB J; 2022 Jun; 36(6):e22336. PubMed ID: 35522243 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review. Amati F; Stainer A; Polelli V; Mantero M; Gramegna A; Blasi F; Aliberti S Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175556 [TBL] [Abstract][Full Text] [Related]
16. Fibrosis on a Chip for Screening of Anti-Fibrosis Drugs. Asmani M; Zhao R Methods Mol Biol; 2021; 2299():263-274. PubMed ID: 34028749 [TBL] [Abstract][Full Text] [Related]
18. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib. Makino S Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766 [TBL] [Abstract][Full Text] [Related]